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Abstract: Lung cancer is the leading cause of cancer deaths worldwide among both men and women, with more than 1 
million deaths annually. Non–small cell lung cancer (NSCLC) accounts for about 80% of all lung cancers. 
Although recent advances have been made in diagnosis and treatment strategies, the prognosis of NSCLC patients is poor 
and it is basically due to a lack of early diagnostic tools. 
However, in the last years genetic and biochemical studies have provided more information about the protein and gene’s 
mutations involved in lung tumors. Additionally, recent proteomic and microRNA’s approaches have been introduced to 
help biomarker discovery. 
Here we would like to discuss the most recent discoveries in lung cancer pathways, focusing on the genetic and epigenetic 
factors that play a crucial role in malignant cell proliferation, and how they could be helpful in diagnosis and targeted 
therapy.  
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INTRODUCTION 
  Lung cancer is the leading cause of cancer-related deaths 
over the world, among both men and women, with an inci-
dence of over 200000 new cases per year and a very high 
mortality rate. It is responsible for more deaths than breast, 
colon and prostate tumors combined [1]. 
  Lung tumors can be divided into two histological groups: 
non-small cell lung cancer (NSCLC) (80.4%) and small cell 
lung cancer (SCLC) (16.8%) [2]. NSCLC, consisting mainly 
of adenocarcinoma, squamous cell and large cell carcinoma, 
accounts for almost 80% of lung cancer cases, whereas 
SCLC is slightly more common and all known cases are due 
to cigarette smoking.  
  Many factors potentially contribute to lung cancer forma-
tion, e.g. tobacco smoke, ionizing radiation and viral infec-
tion, although the mechanisms involved in lung carcinogene-
sis remain largely unknown. 
  Lung cancer is often suspected on the basis of abnormal 
chest imaging and/or non-specific symptoms. Bronchoscopy 
is generally used as an initial diagnostic tool, consisting of 
cytopathologic examination of bronchoalveolar lavage, en-
dobronchial brushings and biopsies from the suspect area.   
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Despite this procedure being specific for lung cancer, its 
sensitivity is low [3]. Therefore, more invasive and expen-
sive diagnostic tests are often required, delaying the diagno-
sis and the subsequent treatment initiation. Indeed, the main 
problem of lung cancer disease is a lack of early-diagnosis 
tools, resulting in more than 60% of patients diagnosed with 
advanced or metastatic disease [4, 5] and therefore not eligi-
ble for a curative surgical resection. 
  The overall five-year survival rate for patients with 
NSCLC is less than 15% and has remained largely un-
changed for the last three decades. Despite new drugs and 
therapeutic regimens, surgical resection remains the most 
promising chance for the ~25% of patients who present 
early-stage disease (stage I-IIIA), although 65% will relapse 
within two years [6].  
  These data suggest that strategies for the early detection 
of lung cancer, aimed at identifying the tumor at a stage in 
which it is small and locally defined, are urgently needed to 
increase significantly the chances of a cure [4]. Recent evi-
dence shows that low dose spiral computed tomography 
(CT) detects lung cancer at smaller sizes and earlier than 
chest X-ray (CXR) that failed to identify 79% of lung can-
cers that were smaller than 2 cm [7]. 
  Another major problem linked to lung cancer disease, as 
for other cancers, is the need to find new and more tailored 
chemotherapeutical. 
  The variable response to chemotherapy with platinum-
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tients crossing from one regimen to another in clinical trials 
commonly show responses [8], suggesting that it might be 
possible to optimize the therapy for individual patients once 
has been determined which regimen would be most effec-
tive.  
  In this short review we summarize what are the main 
genetic alterations involved in lung cancer disease and what 
is the prospective for the future development of new bio-
marker and diagnostic tools to improve the early detection of 
lung cancer.  
GENETIC AND EPIGENETIC ALTERATIONS IN 
LUNG CANCER 
  Different factors contribute to lung cancer formation: 
tobacco smoke, ionizing radiation and viral infection are 
among the most well established. However, the mechanisms 
involved in lung carcinogenesis remain largely unknown to 
date [9]. 
  As most other cancers, several genes are involved in lung 
cancer disease [9], which is initiated by the activation of 
oncogenes or inactivation of tumor suppressor genes [10]. 
 The  proto-oncogene  KRAS is often mutated and is re-
sponsible for 10–30% of lung adenocarcinomas [11, 12]. 
 MYC and Cyclin D1 [13] are amplified and over-
expressed in 2.5–10% and 5% of NSCLC, respectively. 
  ERBB2 (also known as HER-2/neu) or BCL2 over-
expression are involved in 25% of cases [14]. Farther, many 
studies have found ERBB2 mutations (exons 19-20) in a 
small subset of patients. These mutations often represent 
early events in the carcinogenesis of lung adenocarcinoma in 
never smokers [15, 16]. Novel mutations in BRAF were 
identified through systematic resequencing of oncogenes and 
are present in about 2% of adenocarcinoma patients and re-
stricted to tumors that did not show KRAS mutations [17, 
18].  
  The epidermal growth factor receptor (EGFR) that regu-
lates cell proliferation, apoptosis, angiogenesis and tumor 
invasion [11] is over-expressed or in certain cases affected 
by oncogenic mutations in NSCLC and is one of the major 
target for lung cancer therapy. Furthermore, some activating 
mutations in EGFR, mainly deletion mutations in exon 19 
and the single L858R point mutation in exon 21, are associ-
ated with increased response and survival after tyrosine 
kinase inhibitor therapy, whereas the T790M point mutation 
or insertion mutations in exon 20 of EGFR, are associated 
with failure to respond [19-22].  
  Basically, mutations involving EGFR, ERBB2 and 
KRAS are mutually exclusive and are thought to represent 
early events in the carcinogenesis of lung adenocarcinoma in 
never (EGFR  and ERBB2) and current smokers (KRAS) 
[23]. 
  Other oncogenes whose expression has been found al-
tered in lung cancer, include MET,  NKX2-1, and PIK3CA 
[11].  
  The tyrosine kinase protein, SRC is also overexpressed 
and activated in epithelial tumors, and the levels of expres-
sion or activation generally correlate with disease progres-
sion [24], although activating mutations are rare [25]. Stud-
ies have shown that SRC is activated in NSCLC tumor tis-
sues [26, 27], and its inhibition leads to decreased anchor-
age-dependent cell growth and to cell cycle arrest and apop-
tosis [28, 29].  
  Recently, the fusion of the anaplastic lymphoma kinase 
(ALK) with the echinoderm microtubule-associated protein-
like 4 (EML4) has been identified in a subset of NSCLC. 
Approximately 5% of all NSCLC cases contain an EML4-
ALK translocation. It occurs in mutual exclusion to EGFR 
and  KRAS mutations and is associated with nonsmokers. 
Since ALK tyrosine kinase activity is oncogenic both in vitro 
and in vivo, new ALK kinase inhibitors are being evaluated 
in pre-clinical trials for lung cancer [30, 31]. 
  Also, inactivation of tumor suppressor genes plays an 
important role in lung carcinogenesis, as for example the 
tumor suppressor gene TP53 that is mutated in 60–75% of 
lung cancer including both NSCLC and SCLC [32].  
  Another important tumor suppressor gene is LKB1, 
whose loss-of-function mutation/deletion is observed in 30% 
lung adenocarcinomas and 20% of squamous cell carcino-
mas [33, 34].  
  Recently it has been shown a clearly link between SCR 
and LKB1 in NSCLC disease. In particular, SRC and FAK 
signaling pathways are activated in lung cancers when the 
tumor suppressor LKB1 is deleted. These findings suggest 
the use of unique combinatorial therapies for treatment of 
lung cancers [35]. 
  The role of RB family genes in lung cancer malignancy 
has been long examined but remains unclear to date. 
  What is known is that the tumor suppressor RB1 is inac-
tivated in a broad range of human tumors [36, 37], including 
pediatric retinoblastomas and about 90% of human SCLC. 
When RB1 is not itself mutated, other alterations in members 
of the RB pathway are found in human tumors [37-39]. For 
instance, RB1 is rarely found mutated in lung adenocarci-
nomas whereas p16
INK4a, an upstream activator of the RB1 
protein and the two related proteins p107 and p130, is fre-
quently inactivated in this tumor type [40]. 
  Recent studies provided genetic evidence that RB1 and 
p130 have the capacity to act as suppressors of lung adeno-
carcinoma development, confirming the broad tumor-
suppressor potential of the RB family genes and raising the 
possibility that re-activation or induction of RB family func-
tion in lung cancers may be used to slow tumor growth in 
patients [41].  
  Genetic polymorphisms are also indicated to be involved 
in lung carcinogenesis, e.g. interleukin-1 [42], cytochrome 
P450 [43], apoptosis promoters such as caspase-8 [44] and 
DNA repair proteins such as XRCC1 [45].  
  Epigenetic modifications are now well recognized to sig-
nificantly contribute to lung cancer tumorigenesis. For ex-
ample, a great number of aberrantly methylated genes have 
been identified in lung cancer. A well-studied example is the 
aberrant promoter methylation of the tumor suppressor gene 
p16 which leads to gene silencing, an early event in tumori-
genesis [46-48]. Additional examples include H-cadherin 
[49], death-associated protein kinase 1 (DAPK1) [50], 14-3-Lung Cancer  Current Genomics, 2010, Vol. 11, No. 7    515 
3 sigma [51] and the candidate tumor suppressor gene 
RASSF1A [52]. 
  Although research based on known genes, proteins and 
epigenetic alteration has already yielded new information, 
during the past decade the microRNA (miRNA) research-
field has been extensively studied and it may also lend in-
sights into the biology of lung cancer, as well as for cancer 
in general. 
  MiRNAs are small non-coding RNAs about 22 nt long 
that play key roles in gene expression regulation by modulat-
ing the translation and degradation of target mRNAs through 
base pairing to partially complementary sites [53-55]. 
  MmiRNA microarray analysis for lung cancer were re-
cently examined to investigate miRNA involvement in lung 
carcinogenesis and the results obtained show that miRNAs 
could discriminate lung cancers from healthy lung tissues, 
suggesting that miRNA expression profiles could be diag-
nostic and prognostic markers of lung cancer [56] and also 
allow for the differential diagnosis between lung adenocarci-
noma and mesothelioma [57]. 
  Recent studies have reported some examples of miRNAs 
implication in lung cancer. For example miR-29 family 
members directly target both DNA methyltransferases 
DNMT 3A and -3B. In particular, it has been shown that ex-
pression of miR-29 family members is inversely correlated 
with DNMT3A and -3B expression in lung cancers and that 
these miRNAs down-modulate expression levels of both 
enzymes. Furthermore, enforced expressionof these miRNAs 
in lung cancer cells leads to reduced global DNA methyla-
tion, restores expression of TSGs, and inhibits tumorigenic-
ity both in vitro and in vivo [58]. 
  Another important report shows that miR-107 and miR-
185 are down regulated in lung cancer compared with nor-
mal lung and their reintroduction in NSCLC cell lines is able 
to suppress cell growth [59]. Similarly, miR-15a/miR-16, 
which induce RB1-mediated cell cycle arrest by the down-
regulation of G1 cyclins are downregulated in NSCLC [60]. 
  Farthermore, we must remember the role of telomere and 
telomerases that recently have been demonstrated to be in-
volved in lung cancer. 
  Telomeres are nucleoprotein complexes located at the 
end of eukaryotic chromosomes, which role is to prevent 
them from degradation, end to-end fusion and rearrange-
ment. 
  Recently, telomere length has been proposed as prognos-
tic factor in NSCLC, reflecting indirectly chromosomal 
instability. 
  Telomerase and telomeric complex play a key role in 
lung tumor progression. As telomere maintenance is essen-
tial to tumor cell proliferation, several approaches have been 
developed to target either telomerase or telomeric complex. 
Anti telomerase strategies can either target hTERT or 
hTERC, in addition to modulation of telomerase regulators 
at the transcriptional and post-transcriptional levels. More 
recently, the use of specific ligands leading to G quadruplex 
telomeric structure stabilization and therefore to limitation of 
telomerase accessibility to its target appears as a promising 
area of development [61]. 
DIAGNOSTIC TOOLS IN LUNG CANCER 
  Lung cancer is the most prominent cause of cancer-
related mortality worldwide. About 60% of those diagnosed 
with lung cancer die within one year after diagnosis and the 
five-year survival for all patients with lung cancer is only 
16%, a percentage that has not improved significantly in the 
past 10 years [1]. Although many insights into the molecular 
pathology of lung tumors have been achieved, additional 
information is critical for the development of targeted treat-
ments and of early diagnostic methods. Diagnosis and accu-
rate staging of lung cancer is essential for selection of appro-
priate curative or palliative therapy and affects patient prog-
nosis. Both invasive and non-invasive procedures are used 
for this purpose. 
  Thorax computerized tomography (CT) and positron 
emission tomography (PET) are non-invasive techniques 
used to detect lymph node involvement and histological 
sampling of lymph nodes, but often these techniques are not 
sufficient and thus invasive techniques such as transbron-
chial needle aspiration (TBNA), needle aspiration by endo-
bronchial ultrasound (EBUS) and mediastinoscopy are fre-
quently used to recover histological samples from lymph 
nodes [62]. Since patients often present poor general condi-
tions or severe hypoxemia due to coexisting diseases 
(COPD, heart failure, etc.), it may not be possible to use in-
vasive procedures for diagnosis and staging in some of the 
patients with lung cancer. 
  Recent studies provided first evidence for the potential 
usefulness of a blood-based test for lung cancer diagnosis 
[63]. 
  For example the mutational status of EGFR can be read-
ily detected in primary tumors and the correlation between 
EGFR mutations and EGFR TKI (Tyrosine Kinase Inhibi-
tors) sensitivity has been validated in several clinical trials, 
but it may be difficult to obtain tumor tissues for such analy-
sis. Therefore, since plasma samples of patients with NSCLC 
often contain circulating DNA derived from tumor tissues, 
plasma samples have been used for detecting genetic altera-
tions, in particular for EGFR [64].  
  The research of new biomarkers is important not only for 
improving diagnosis but also it may offer promise in opti-
mizing treatment. Understanding the genetic mechanisms 
affecting drug activity and response to treatment is a major 
challenge for establishing an individualized chemotherapy.  
  To date, cisplatin and platinum-containing drugs are rou-
tinely used for treatment of NSCLC and are known to have 
vital role. 
  DNA adducts, due to cisplatin treatment, are mainly re-
paired by nucleotide excision repair pathway and proteins 
such as excision repair cross complementing 1 (ERCC1), 
ribonucleotide reductase subunit M1 (RRM1) and breast 
cancer susceptibility gene 1 (BRCA1) have an important role 
in this process.  
  Recently, ERCC1, RRM1 and BRCA1 and TS 
(Thymidylate synthase) [65] have been confirmed as predic-
tive markers of treatment response and survival benefit in 
patients with lung cancer and prospective studies investigat-
ing the efficacy of their determination in larger set of pa-
tients are currently ongoing [66]. 516    Current Genomics, 2010, Vol. 11, No. 7  Esposito et al. 
  But to date more than two thirds of lung cancer tumors 
are diagnosed at late stages when the survival rate is low [4] 
and thus the main purpose and also the major obstacle of 
lung cancer research therapy is to detect lung cancer at an 
early stage and when it is still locally defined. 
CONCLUSIONS 
  Lung cancer is the leading cause of death over the world 
and the only chance of cure for patients affected from this 
kind of cancer is surgical resection. 
  This is mainly due to the fact that several factors are in-
volved in lung cancer develoment and progression and to 
date the diagnostic methods available for an early and effi-
cient detection are not sufficient. 
  Although lung cancer research data have accumulated 
dramatically during the past several years, there is no data-
base specifically focusing on lung cancer molecular biology 
available yet. 
  In this short review we have summarized some of the 
factors contributing to lung cancer, but it is just an overview 
of the most important proteins involved in lung cancer dis-
ease, which are often mutated or present an unusual pattern 
of expression compared to the healthy tissue. 
  All together these data are important for understanding 
the nature behind this type of cancer and also to understand 
that basic research on proteins, miRNAs and all the other 
epigenetic modifications could be used to develop more 
powerful diagnostic tools, as well as prognostic or predictive 
markers or even for the development of new targeting thera-
pies for lung cancer. 
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